A Phase II Evaluation of the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Persistent or Recurrent Endometrial Cancer
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 50
- 试验地点
- 2
- 主要终点
- Objective response rate (ORR)
研究概览
简要总结
The purpose of this study is to evaluate the activity and safety profile of mirvetuximab soravtansine (IMGN853) in patients with type II endometrial cancers that overexpress folate receptor alpha (FRα).
详细描述
This study will enroll patients with persistent or recurrent FRα-positive uterine serous carcinoma (pure or mixed), Grade 3 endometrial adenocarcinoma, or carcinosarcoma with high grade serous or Grade 3 endometrioid components. All patients must have measurable disease. The primary objective of the study is to assess the activity of IMGN853 as measured by objective response rate (ORR). The secondary objectives are to assess the duration of overall survival (OS), progression-free survival (PFS) and durable disease control rate (DDCR), as well as the safety profile of IMGN853 in endometrial carcinoma patients. Exploratory/correlative objectives are to correlate ORR, PFS, and OS with the level of folate receptor α expression and explore use of circulating tumor (ct) DNA as a biomarker for disease response and compare its performance to cancer antigen 125 (CA-125). All enrolled patients will receive IMGN853 at a dose of 6 mg/kg administered intravenously once every 3 weeks until unacceptable toxicity or progression of disease requiring discontinuation of treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 100 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Radiologically confirmed (ie, CT scan and/or MRI) persistent or recurrent endometrial cancer
- •Patients must have one of the following pathologically documented, definitively diagnosed tumor types: Uterine serous carcinoma (Pure or Mixed), Grade 2 or Grade 3 endometrial adenocarcinoma, Carcinosarcoma with high grade serous or Grade 2/3 endometrioid components, or clear cell carcinoma (Pure or Mixed).
- •Have measurable disease
- •FRα-positive tumor expression as defined in the protocol
- •Have at least one "target lesion" to be used to assess response as defined by RECIST v1.1
- •Patients must have received prior treatment with ≤ 3 prior lines of therapy for recurrent disease; hormonal agents are not considered a line of therapy; prior treatment with folate receptor-targeting investigational agents is not allowed
- •Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- •Time from prior therapy: Systemic anti-neoplastic therapy: five half-lives or four weeks, whichever is shorter; Radiotherapy: wide-field radiotherapy completed at least four weeks, or focal radiation completed at least two weeks, prior to starting study treatment
- •Patients must have resolution of toxic effect(s) of the most recent prior chemotherapy
- •Patients must have adequate hematologic, liver and kidney function as defined in the protocol
- •Women of child bearing potential (WCBP), must agree to use effective contraceptive methods during study treatment and for at least twelve weeks after the last dose of IMGN853
- •WCBP must have a negative pregnancy test within 4 days prior to the first dose of study treatment
- •At time of initial surgery, patient may have either been optimally or suboptimally debulked
- •Have signed the informed consent form, and willing to adhere to the study visit schedule and other protocol requirements
- •≥ 18 years of age
排除标准
- •Active or chronic corneal disorder
- •Serious concurrent illness or clinically-relevant active infection as defined in the protocol
- •Clinically-significant cardiac disease such as recent myocardial infarction (≤ 6 months prior to day 1), unstable angina pectoris, uncontrolled congestive heart failure, uncontrolled hypertension, prior history of hypertensive crisis or hypertensive encephalopathy, uncontrolled cardiac arrhythmias, clinically-significant vascular disease, severe aortic stenosis, clinically significant peripheral vascular disease, or cardiac toxicity following prior chemotherapy
- •History of neurological conditions
- •History of hemorrhagic or ischemic stroke within the last 6 months
- •History of cirrhotic liver disease
- •Previous clinical diagnosis of non-infectious pneumonitis
- •Prior hypersensitivity to monoclonal antibodies
- •Women who are pregnant or breast feeding
- •Carcinomatous meningitis, untreated central nervous system (CNS) disease or symptomatic CNS metastasis
- •History or evidence of thrombotic or hemorrhagic disorders within 6 months before first study treatment
- •Required used of folate-containing supplements (e.g. folate deficiency)
- •Has a known additional malignancy that is progressing or required active treatment within 3 years of first dose of study treatment
研究组 & 干预措施
IMGN853
IMGN853 administered 6 mg/kg adjusted ideal body weight (AIBW) once every three weeks (Q3W)
干预措施: IMGN853 (Drug)
结局指标
主要结局
Objective response rate (ORR)
时间窗: 5 Years
Objective response rate (complete response and partial response rates) by RECIST 1.1 criteria of mirvetuximab soravtansine in patients with folate receptor α-positive persistent or recurrent endometrial cancer
次要结局
- Duration of overall survival (OS)(5 Years)
- Safety profile of mirvetuximab soravtansine (IMGN853) in endometrial cancer patients (adverse events as assessed by CTCAE v5.0)(5 Years)
- Durable disease control rate (DDCR)(5 Years)
- Duration of progression free survival (PFS)(5 Years)
研究者
Alessandro Santin
Professor of Obstetrics, Gynecology, and Reproductive Sciences
Yale University